Skip to main content
. Author manuscript; available in PMC: 2021 Sep 6.
Published in final edited form as: Mol Cancer Ther. 2021 Jun 22;20(9):1592–1602. doi: 10.1158/1535-7163.MCT-21-0074

Figure 5. NSG mice implanted with EBV+ human B-cells and treated with ch128.1/IgG1 showed significantly reduced plasma levels of human inflammatory cytokines, immunoregulatory molecules, and soluble factors.

Figure 5.

Plasma levels of human IL-6 (A), human IL-18 (B), human IFN-γ (C), human TNF-α (D), human CXCL10 (E), human IL-10 (F), human sCD25 (G), and sCD27 (H) were measured by multiplex immunometric assays. Results are provided for each experimental group and included are the combined results of 2-independent experiments for mice implanted with EBV− or EBV+ B-cells and treated with ch128.1/IgG1 or IgG1 control. Bars indicate geometric mean values. Also shown are mean values for each molecule in healthy human plasma samples (Lab QC). Nonparametric, unpaired Mann-Whitney tests were conducted, where *p = 0.01–0.05, **p = 0.00–0.01, ***p = 0.0001–0.001, ****p <0.0001, and ns, not significant.